Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Jan 30;96(4):1547-1555.
doi: 10.1021/acs.analchem.3c04242. Epub 2024 Jan 12.

Facilitated Transport of EGFR Inhibitors Plays an Important Role in Their Cellular Uptake

Brian S Wong  1 , Erin L Dunnington  1 , Ruibing Wu  1 , Jonathan I Kim  1 , Kailun Hu  1 , Thomas H Ro  1 , Dan Fu  1
Affiliations

Facilitated Transport of EGFR Inhibitors Plays an Important Role in Their Cellular Uptake

Brian S Wong et al. Anal Chem. .

Abstract

Epidermal growth factor receptor (EGFR) is a transmembrane protein commonly targeted by tyrosine kinase inhibitors (TKIs) as a front-line therapy for patients with many cancers including nonsmall cell lung cancer (NSCLC). Effective treatment requires efficient intracellular drug uptake and target binding. However, despite the recent success in the development of new TKI drugs, the mechanisms of uptake for many TKIs are still poorly understood due to the difficulty in imaging and measuring nonfluorescent drug molecules at a subcellular resolution. It has previously been shown that weakly basic TKI drugs are sequestered in lysosomes. Leveraging this property, we apply hyperspectral stimulated Raman scattering imaging to directly visualize and quantify two Food and Drug Administration-approved EGFR inhibitor drugs (lapatinib and afatinib) inside living cells and the changes in their cellular uptake upon the addition of organic cation transporter inhibitors. These single-cell quantitative measurements provide new insight into the role of membrane transporters in the uptake of TKI drugs in living cells.

PubMed Disclaimer

Similar articles

See all similar articles

Cited by

References

    1. Zhong L; Li Y; Xiong L; Wang W; Wu M; Yuan T; Yang W; Tian C; Miao Z; Wang T; Yang S Small Molecules in Targeted Cancer Therapy: Advances, Challenges, and Future Perspectives. Signal Transduct. Target. Ther. 2021, 6 (1), 1–48. 10.1038/s41392-021-00572-w. - DOI - PMC - PubMed
    1. Sierra JR; Cepero V; Giordano S Molecular Mechanisms of Acquired Resistance to Tyrosine Kinase Targeted Therapy. Mol. Cancer 2010, 9, 75. 10.1186/1476-4598-9-75. - DOI - PMC - PubMed
    1. Du Z; Lovly CM Mechanisms of Receptor Tyrosine Kinase Activation in Cancer. Mol. Cancer 2018, 17 (1), 58. 10.1186/s12943-018-0782-4. - DOI - PMC - PubMed
    1. Neul C; Schaeffeler E; Sparreboom A; Laufer S; Schwab M; Nies AT Impact of Membrane Drug Transporters on Resistance to Small-Molecule Tyrosine Kinase Inhibitors. Trends Pharmacol. Sci. 2016, 37 (11), 904–932. 10.1016/j.tips.2016.08.003. - DOI - PubMed
    1. Giacomini KM; Huang S-M; Tweedie DJ; Benet LZ; Brouwer KLR; Chu X; Dahlin A; Evers R; Fischer V; Hillgren KM; Hoffmaster KA; Ishikawa T; Keppler D; Kim RB; Lee CA; Niemi M; Polli JW; Sugiyama Y; Swaan PW; Ware JA; Wright SH; Wah Yee S; Zamek-Gliszczynski MJ; Zhang L; The International Transporter Consortium. Membrane Transporters in Drug Development. Nat. Rev. Drug Discov. 2010, 9 (3), 215–236. 10.1038/nrd3028. - DOI - PMC - PubMed

Publication types

MeSH terms

-